Vertex Pharmaceuticals Incorporated with ticker code (VRTX) now have 26 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $577.00 and $325.00 and has a mean share price target at $473.61. (at the time of writing). Given that the stocks previous close was at $470.28 this would indicate that there is a potential upside of .7%. It’s also worth noting that there is a 50 day moving average of $446.71 and the 200 moving average now moves to $406.70. The company has a market capitalization of 122.06B. The stock price is currently at: $473.02 USD
The potential market cap would be $122,928,547,355 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 30.66, revenue per share of $39.49 and a 12.82% return on assets.
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
